|Day Low/High||19.89 / 20.73|
|52 Wk Low/High||11.17 / 21.25|
Horizon Pharma plc (Nasdaq: HZNP) today announced that it has received two Notices of Allowance from the United States Patent and Trademark Office for U.
Horizon Pharma plc (Nasdaq: HZNP) announced today that its second-quarter financial results will be released on Wednesday, August 8, 2018.
These names are showing bullish and bearish technical patterns over the past week.
The endowment will support a clinical care team dedicated to providing rare disease patients with earlier intervention and more consistent treatment over the course of their lifetimes
Investors in Horizon Pharma plc saw new options begin trading this week, for the May 18th expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 98 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.
While Donald Trump's tweets can shake up pharmaceutical stocks, history suggests that investors have little to fear from the president's drug pricing rhetoric.
Agreement Aims to Further Expand Growing Gout Franchise
The Dublin firm on Nov. 6 unveiled third-quarter numbers that topped analysts' estimates and raised its full-year net sales outlook and the lower end of its 2017 adjusted Ebitda guidance.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.